Astria Therapeutics Inc News

Express News | Citizens Capital Markets Reiterates Market Outperform on Astria Therapeutics, Maintains $26 Price Target

BenzingaMar 3 09:55 ET

TD Cowen Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $35

Moomoo NewsMar 1 13:31 ET · Ratings

LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsFeb 27 14:32 ET · Ratings

Express News | Astria Therapeutics Initiates Alpha-Orbit Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

ReutersFeb 27 08:00 ET

Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Yahoo FinanceFeb 22 08:01 ET

JMP Securities Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $26

Moomoo NewsFeb 18 10:31 ET · Ratings

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

Business WireFeb 4 08:00 ET

Astria Therapeutics Initiated at Market Outperform by JMP Securities

Dow JonesJan 31 12:09 ET · Ratings

JMP Securities Initiates Astria Therapeutics Inc(ATXS.US) With Buy Rating, Announces Target Price $26

Moomoo NewsJan 31 01:32 ET · Ratings

Express News | Astria Therapeutics Announces Initiation of Phase 1a Trial of Star-0310, a Potential Best-in-Class Monoclonal Antibody Ox40 Antagonist for the Treatment of Atopic Dermatitis

ReutersJan 23 08:00 ET

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

BusinesswireJan 23 08:00 ET

Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsJan 16 08:31 ET · Ratings

LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Cuts Target Price to $22

Moomoo NewsJan 14 08:31 ET · Ratings

Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $32

Moomoo NewsJan 14 08:31 ET · Ratings

Express News | Astria Therapeutics Inc : Jefferies Raises Target Price to $29 From $27

ReutersJan 13 10:39 ET

Astria Therapeutics Announces ALPHA-ORBIT Phase 3 Trial Design For Navenibart In HAE; Features 3- And 6-Month Dosing, Primary Analysis At 6 Months; Expected Q1 2025 Initiation And Early 2027 Results; Strong Financial Position Supports Until Top-Line...

BenzingaJan 13 08:20 ET

Express News | Astria Therapeutics Inc: Alpha-Orbit Top-Line Results Anticipated in Early 2027.

ReutersJan 13 08:03 ET

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Business WireJan 13 08:00 ET

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BusinesswireJan 3 16:10 ET

Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersJan 3 16:10 ET